AstraZeneca’s Oral GLP-1 Moves Into Late-Stage Trials as the Weight-Loss Drug Race Shifts From Syringes to Pill Boxes
elecoglipron delivered double-digit weight loss in a mid-stage trial, bringing AstraZeneca closer to the oral obesity drug market; but efficacy, tolerability, and differences from similar drugs will only become truly clear in Phase 3.